参考文献/References:
[1].王一范,占小江,陈岩冰,等. 腹膜透析患者退出原因分析[J]. 中华肾脏病杂志,2019,35(4):275-280.
[2].Rroji M,Cafka M,Seferi S,et al. The potential effect of cardiac function on pulmonary hypertension,other risk factors,and its impact on survival in dialysis patients[J].?Int Urol Nephrol,2021,53(2):343-351.
[3].万骋,曹东维,张庆燕,等. 肺动脉高压与维持性血液透析患者心血管事件和全因死亡的关系[J]. 海南医学院学报,2019,25(6):438-442.
[4].Zhang X,Zhao W,Ma X,et al. Prognostic value of pulmonary hypertension in pre-dialysis chronic kidney disease patients[J].?Int Urol Nephrol,2020,52(12):2329-2336.
[5].李明,叶增纯,李灿明,等. 维持性血液透析患者合并肺动脉高压的临床及预后分析[J]. 中华肾脏病杂志,2019(4):241-246.
[6].Afzal A,Bhatti MA,Manzoor S. Pulmonary hypertension:an emerging problem in patients undergoing regular hemodialysis[J].?J Coll Physicians Surg Pak,2018,28(8):594-596.
[7].刘慧珍,贾强,郑霖. 不同血液透析膜对尿毒症患者肺功能的影响[J]. 中华实用诊断与治疗杂志,2017,31(11):1122-1125.
[8].Borba GC,Andrade FP,de Souza Ferreira T,et al. Estimation of pulmonary artery systolic pressure in hemodialysis patients and its association with cardiorespiratory fitness and pulmonary function[J].?Int Urol Nephrol,2023,55(4):961-968.
[9].Kiykim AA,Horoz M,Ozcan T,et al. Pulmonary hypertension in hemodialysis patients without arteriovenous fistula:the effect of dialyzer composition[J].?Ren Fail,2010,32(10):1148-1152.
[10].叶小文. 血液透析与腹膜透析对尿毒症患者肺动脉高压的影响[J]. 皖南医学院学报,2018,37(3):268-270,273.
[11].刘喜鸿,郭顺华,过新民,等. 血液透析动静脉内瘘对肺动脉压力的影响[J]. 中国处方药,2021,19(2):161-162.
[12].屈斌,张倩,高弼虎. 维持性血液透析患者不同血管通路类型的临床特征及全因死亡差异比较[J]. 中国血液净化,2021,20(06):367-372.
[13].王倩,裴荣光,于明忠,等. 维持性血液透析患者肺动脉高压的临床研究[J]. 中国煤炭工业医学杂志,2014,17(8):1292-1295.
[14].Sathiavageesan S,Shanmugam VB,Sundaram V. The impact of vascular access location on pulmonary arterial pressure in chronic kidney disease patients undergoing hemodialysis[J].Semin Dial,2024,37(1):65-71.
[15].Unal A,Duran M,Tasdemir K,et al. Does arterio-venous fistula creation affects development of pulmonary hypertension in hemodialysis patients? [J].?Ren Fail ,2013,35(3):344-351.
[16].Hudson J,Farkas L. Epigenetic regulation of endothelial dysfunction and inflammation in pulmonary arterial hypertension[J].?Int J Mol Sci.,2021,22(22):12098.
[17].王晓娜,周芸. 慢性肾脏病尿毒症毒素相关血管内皮细胞功能障碍机制的研究进展[J]. 山东医药,2021,61(22):104-107.
[18].马晶晶,崔雅茜,石琳.儿童原发性高血压与血管内皮细胞的关系[J]. 中国医刊,2019,54(11):1183-1186.
[19].王启鹏,董洪,刘建香,等.血液透析患者并发肺动脉高压时缺氧诱导因子-1α的水平[J]. 中国老年学杂志,2016,36(1):87-90.
[20].Telo S,K?rk?l G,Kulu?ztürk M,et al. Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive pulmonary disease? [J].?Clin Respir J,2018,12(4):1433-1438.
[21].陈英,袁红英. 前列地尔对维持性血液透析患者肺动脉高压的治疗效果评价[J]. 中国实用医药,2022,17(27):142-145.
[22].Tuttle M,Sarnak MJ,Navaneethan SD. Therapeutic approaches for pulmonary hypertension in patients with chronic kidney disease[J].Curr Opin Nephrol Hypertens,2024,33(5):494-502.
[23].麦湘湘,李柠肖,庄乙君. 多频生物电阻抗评价透析前慢性肾脏病5期患者容量状态及其与肺动脉高压的相关性[J]. 西部医学,2021,33(4):535-540.
[24].Nekooeian M,Ezzatzadegan Jahromi S,Masjedi F,et al. The significance of volume overload in the development of pulmonary arterial hypertension in continuous ambulatory peritoneal dialysis patients[J].?Ther Apher Dial,2023,27(4):760-770.
[25].Y?lmaz S,Yildirim Y,Taylan M,et al. The relationship of fluid overload as assessed by bioelectrical impedance analysis with pulmonary arterial hypertension in hemodialysis patients[J].?Med Sci Monit,2016,22:488-494.
[26].Deschle HA,Amenabar A,Casso NA,et al. Behavior of right atrial strain in high systolic pulmonary artery pressure[J].?Echocardiography,2018,35(10):1557-1563.
[27].Orihuela O,de Jesus Ventura M,Carmona-Ruiz HA,et al. Pulmonary hypertension in patients starting peritoneal dialysis[J].?Arch Med Res,2020,51(3):254-260.
[28].姚春萌,周礼平,郭汉城,等. 腹膜透析患者发生肺动脉高压危险因素分析[J]. 中国血液净化,2017,16(4):162-165.
[29].Unal A,Sipahioglu M,Oguz F,et al. Pulmonary hypertension in peritoneal dialysis patients:prevalence and risk factors[J].?Perit Dial Int,2009,29(2):191-198.
[30].Hu Y,Wang X,Xiao S,et al. Development and validation of a risk nomogram model for predicting pulmonary hypertension in patients with stage 3-5 chronic kidney disease[J].?Int Urol Nephrol,2023,55(5):1353-1363.
[31].Etemadi J,Zolfaghari H,Firoozi R,et al. Unexplained pulmonary hypertension in peritoneal dialysis and hemodialysis patients[J].?Rev Port Pneumol,2012,18(1):10-14.
[32].高琛妮,张瑞梅,杨双吉,等. 云南省单中心维持性血液透析患者并发肺动脉高压的临床特征及危险因素分析[J]. 云南医药,2021,42(4):317-321.
[33].欧琴琴,查艳. 维持性血液透析患者营养不良与认知损害的研究进展[J]. 中华肾脏病杂志,2022,38(11):1006-1010.
[34].Snipelisky D,Jentzer J,Batal O,et al. Serum albumin concentration as an independent prognostic indicator in patients with pulmonary arterial hypertension[J].?Clin Cardiol,2018,41(6):782-787.
[35].Yu Q,Zhang Q. Pulmonary hypertension in hemodialysis patients and its determinants:a hospital based cross-sectional study[J].?Int J Gen Med,2024,17:3919-3926.
[36].杜琇,郑峰,姜燕,等. 老年腹膜透析患者肺动脉高压发生情况及其危险因素分析[J]. 老年医学与保健,2022,28(2):300-304.
[37].Roumeliotis S,Dounousi E,Salmas M,et al. Vascular calcification in chronic kidney disease:the role of vitamin K-dependent Matrix Gla Protein[J]. Front Med (Lausanne),2020,7:154.
[38].Chuang KH,Yao RH,Jiang YN,et al. Attenuating effect of magnesium on pulmonary arterial calcification in rodent models of pulmonary hypertension[J].?J Hypertens,2022,40(10):1979-1993.
[39].Miri M,Ahmadi M,Hatami M. Correlation between fibroblast growth factor-23 and pulmonary arterial hypertension in hemodialysis patients[J].?Iran J Kidney Dis,2021,15(4):300-305.
[40].许嵘,吕文律,曹学森,等. 维持性血液透析患者发生肺动脉高压的危险因素分析[J]. 实用心脑肺血管病杂志,2023,31(2):44-47,52.
[41].Lin C,Ge Q,Wang L,et al. Predictors,prevalence and prognostic role of pulmonary hypertension in patients with chronic kidney disease:a systematic review and meta-analysis[J].?Ren Fail,2024,46(2):2368082.
[42].Nickel NP,de Jesus Perez VA,Zamanian RT,et al. Low-grade albuminuria in pulmonary arterial hypertension[J].?Pulm Circ,2019,9(2):2045894018824564.
[43].Liu X,Li X,Duan J,et al. The percentage of circulating fibrocytes is associated with increased morbidity of pulmonary hypertension in patients on hemodialysis[J]. Semin Dial,2024,37(1):43-51.
[44].杨禄颜,廖文胜,谭晓燕. 高通量透析联合贝前列素对维持性血液透析患者并发肺动脉高压的疗效分析[J]. 黑龙江医学,2017,41(2):113-114.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(7):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(7):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(7):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(7):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(7):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(7):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(7):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(7):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(7):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]